BeiGene
BGNE
#966
Rank
โ‚น1.764 T
Marketcap
โ‚น16,128
Share price
0.49%
Change (1 day)
15.97%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -โ‚น72.75 Billion

According to BeiGene 's latest financial reports the company's current earnings are โ‚น3.31 Billion. In 2023 the company made an earning of -โ‚น105.46 Billion, an increase over its 2022 earnings that were of -โ‚น156.27 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚น72.75 Billion-31.02%
2023 -โ‚น105.46 Billion-32.52%
2022 -โ‚น156.27 Billion24.39%
2021 -โ‚น125.63 Billion-13.21%
2020 -โ‚น144.74 Billion72.69%
2019 -โ‚น83.82 Billion36.01%
2018 -โ‚น61.63 Billion616.83%
2017 -โ‚น8.6 Billion-15.24%
2016 -โ‚น10.15 Billion107.91%
2015 -โ‚น4.88 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น1.59 Billion-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น10.29 Billion-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA